Lanean...
The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics
Fimasartan, the eighth angiotensin receptor blocker, was launched in March 2011 and was found to have an excellent efficacy and safety profile in a large cross-sectional population study [Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb); Park et al.: Am J Cardio...
Gorde:
| Argitaratua izan da: | Pulse |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
S. Karger AG
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4315348/ https://ncbi.nlm.nih.gov/pubmed/26587436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000360965 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|